 Home > Medical News > Latest Medical News > Haichuang Pharmaceutical's Phase 1 clinical trial of oral PROTAC therapy achieved the first patient dosing

Haichuang Pharmaceutical's Phase 1 clinical trial of oral PROTAC therapy achieved the first patient dosing

 Last Update: 2022-02-19
 Source: Internet
 Author: User

Tags

protein spinal fluid

what considered protein

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On January 19, 2022, Haichuang Pharmaceutical announced that its drug candidate HP518, an oral protein-targeted degradation chimera (PROTAC) targeting androgen receptor (AR), achieved the first patient delivery in the Phase 1 clinical trial in Australia.

Protein degradation therapy represented by PROTAC has received unprecedented attention in the past year

(Original abridged)

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.